GSK and Shionogi have agreed with Pfizer to restructure ViiV Healthcare’s shareholder base, with Shionogi replacing Pfizer’s 11.7 percent economic interest and increasing its stake to 21.7 percent, ...

GSK has agreed to acquire RAPT Therapeutics in a transaction valued at approximately $2.2 billion, adding ozureprubart, a phase IIb long-acting anti-IgE antibody for food allergy prevention, to its ...